JFG
LGND icon

Jefferies Financial Group’s Ligand Pharmaceuticals LGND Stock Holding History

Jefferies Financial Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,315
Closed -$1.46M – 1872
2026
Q1 		$1.46M Buy
+7,315
New +$1.45M 0.01% 769

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jefferies Financial Group's LGND Position: Q2 2026 in Review

Jefferies Financial Group sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 7,315 shares — an estimated $1.46M sold.

Jefferies Financial Group first reported a position in LGND in Q1 2026 and held it in 1 quarter. The position peaked at $1.46M in Q1 2026. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Jefferies Financial Group reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 7,315 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.46M.
  • Jefferies Financial Group first reported a position in Ligand Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Jefferies Financial Group's Ligand Pharmaceuticals position peaked at $1.46M in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.